Celgene (CELG) Upgraded by BidaskClub to “Sell”

BidaskClub upgraded shares of Celgene (NASDAQ:CELG) from a strong sell rating to a sell rating in a report released on Wednesday.

CELG has been the topic of a number of other research reports. Cantor Fitzgerald began coverage on Celgene in a research note on Monday, October 1st. They set an overweight rating and a $100.00 price objective on the stock. Mizuho set a $117.00 price objective on Celgene and gave the stock a buy rating in a research note on Tuesday, October 30th. JPMorgan Chase & Co. restated a buy rating on shares of Celgene in a research note on Thursday, October 11th. Cann restated a buy rating on shares of Celgene in a research note on Monday. Finally, UBS Group set a $94.00 price objective on Celgene and gave the stock a buy rating in a research note on Saturday, October 27th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $116.99.

Shares of CELG opened at $72.47 on Wednesday. The stock has a market cap of $50.67 billion, a price-to-earnings ratio of 10.60, a P/E/G ratio of 0.45 and a beta of 1.50. Celgene has a 12 month low of $66.62 and a 12 month high of $110.81. The company has a debt-to-equity ratio of 4.06, a quick ratio of 1.99 and a current ratio of 2.13.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $2.29 EPS for the quarter, topping the Zacks’ consensus estimate of $2.02 by $0.27. The company had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. As a group, equities research analysts predict that Celgene will post 7.45 earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in CELG. Ayalon Holdings Ltd. acquired a new stake in Celgene during the second quarter valued at approximately $100,000. Atlantic Trust LLC acquired a new stake in Celgene during the second quarter valued at approximately $101,000. Moneta Group Investment Advisors LLC raised its stake in Celgene by 2,688.6% during the second quarter. Moneta Group Investment Advisors LLC now owns 10,290 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 9,921 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new stake in Celgene during the third quarter valued at approximately $132,000. Finally, City Holding Co. acquired a new stake in Celgene during the second quarter valued at approximately $143,000. Institutional investors and hedge funds own 72.87% of the company’s stock.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Read More: What is the Coverage Ratio?

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply